Global meeting to facilitate multidisciplinary debate on the risks
and benefits of antithrombotic therapy.
With a wealth of new data supporting the role of antithrombotic drugs in cardiovascular disease (CVD) prevention reaching publication over the last few years, the opportunity for world experts from a mix of disciplines to meet and put this evidence into clear perspective is both timely and invaluable. The International Aspirin Foundation Conference will provide the scientific arena to enable this important discussion to take place at its 2019 Scientific Conference in Rome on the 28th June.
In the morning Professor Andrew Chan (Harvard University) and Professor Peter Rothwell (University of Oxford) will co-chair a session in which the benefits and risks of antithrombotic therapy in secondary disease prevention is examined. Speakers will discuss the trials in which one antiplatelet drug is dropped from dual or triple antithrombotic therapy; the evidence for combining antiplatelet and anticoagulant strategies in high-risk patients and the extent to which upper gastrointestinal bleeding events might be reduced with more extensive use of gastroprotectant agents.
Professor Michael Gaziano (Harvard University) and Professor John Chia (National Cancer Centre, Singapore) are Chairpersons for the afternoon session in which the risks and benefits of antithrombotic therapy for the primary prevention of CVD are reviewed. This will include recent studies on optimizing the aspirin dosing regimen; incorporating other benefits of low-dose aspirin in the benefit/risk equation, as well as the need for targeting the right patient population for primary prevention.
Professor Carlo Patrono (Catholic University of Rome), Chair of the International Aspirin Foundation’s Scientific Advisory Board states; “This is an exciting opportunity to review and discuss recent advances in antithrombotic therapy, from both a basic science and clinical perspective, and to revisit aspirin’s role in modern medicine”.
For further information and a full programme visit our websiteThe conference is open to both academics and medical professionals, but tickets are limited. To secure your place visit our Eventbrite booking page